Security record · archived quarter
NVS
Novartis AG · Healthcare · Drug Manufacturers - General
3Tracked holders
0Δ holders
239.53KShares held
$32.26MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 239.53K | $32.26M | n/a | n/a |
| Q2 2026 | 124 | 0 | 102.38M | $16.04B | +8 | −8 |
| Q1 2026 | 126 | +1 | 113.27M | $17.29B | +8 | −7 |
| Q4 2025 | 124 | +1 | 102.45M | $14.13B | +1 | n/a |
| Q3 2025 | 20 | -1 | 49.48M | $6.35B | n/a | −1 |
| Q2 2025 | 18 | 0 | 41.97M | $5.08B | +2 | −2 |
| Q1 2025 | 16 | +1 | 41.02M | $4.58B | +1 | n/a |
| Q4 2024 | 15 | +1 | 35.01M | $3.41B | +1 | n/a |
| Q3 2024 | 13 | 0 | 33.66M | $3.89B | n/a | n/a |
| Q2 2024 | 13 | n/a | 33.92M | $3.61B | n/a | n/a |
Who holds it · Q3 2026
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 135.55K | -10.0% | $17.58M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 2 | TD Waterhouse Canada Inc. | 103.91K | +20.2% | $14.66M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | Ninety One UK Ltd | 76 | 0.0% | $10,836 | 0.0% | Held | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 2 holders, 1.31M shares, $431.09M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2026 ·
Methodology ·
Get this via the API